Bio-Techne Corporation (TECH) is a Biotechnology company in the Healthcare sector, currently trading at $58.66. It has a SharesGrow Score of 64/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of TECH = $27.22 (-53.6% from the current price, the stock appears overvalued). Analyst consensus target is TECH = $69 (+18.2% upside).
Valuation: TECH trades at a trailing Price-to-Earnings (P/E) of 104.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 10.64.
Financials: revenue is $1.2B, +3.3%/yr average growth. Net income is $73M, growing at -30.9%/yr. Net profit margin is 6% (thin). Gross margin is 64.8% (-3.6 pp trend).
Balance sheet: total debt is $444M against $1.9B equity (Debt-to-Equity (D/E) ratio 0.23, conservative). Current ratio is 3.46 (strong liquidity). Debt-to-assets is 17.4%. Total assets: $2.6B.
Analyst outlook: 18 / 25 analysts rate TECH as buy (72%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 27/100 (Fail), Growth 30/100 (Fail), Past 100/100 (Pass), Health 100/100 (Pass), Moat 65/100 (Partial), Future 79/100 (Pass), Income 45/100 (Partial).
